CASP10 Antibody

What is CASP10 and its functional significance in apoptotic pathways?

CASP10 (Caspase 10) is a member of the peptidase C14A family that contains two death effector domains (DED). It functions upstream in the apoptosis cascade and is recruited to both Fas- and TNFR-1 receptors in a FADD-dependent manner. Once activated, CASP10 can cleave and activate effector caspases including CASP3, CASP4, CASP6, CASP7, CASP8, and CASP9 . This caspase has been implicated in the granzyme B apoptotic pathway and plays a critical role in lymphocyte homeostasis, with mutations associated with autoimmune lymphoproliferative syndrome (ALPS) and non-Hodgkin lymphomas .

What criteria should be considered when selecting a CASP10 antibody for research applications?

When selecting a CASP10 antibody, researchers should consider:

• Antibody type: Monoclonal antibodies (like clone 4C1 from MBL) offer high specificity , while polyclonal antibodies may provide broader epitope recognition but potential batch variability.

• Target region specificity: Determine whether the antibody targets the prodomain, p17 large protease subunit, or p12 small protease subunit, as these regions have different functional significance .

• Isoform detection: Consider which CASP10 isoforms are recognized, as some isoforms (like isoform 7) can enhance NF-kappaB activity while promoting only slight apoptosis, while others (like isoform C) are proteolytically inactive .

• Validated applications: Verify that the antibody has been validated for your specific application (WB, IHC, ICC/IF, IP) with published references .

• Species reactivity: Most CASP10 antibodies are validated for human samples, with limited cross-reactivity to other species .

What are the optimal conditions for detecting CASP10 expression by Western blot?

For optimal CASP10 detection by Western blot:

• Sample preparation: Use fresh cell lysates from relevant cell lines known to express CASP10 (e.g., Jurkat, KG-1, HeLa) .

• Protein amount: Load 20-50 μg of total protein per lane.

• Antibody dilution: Use the manufacturer's recommended dilution, typically 1:500-1:1000 for polyclonal antibodies .

• Detection system: HRP-conjugated secondary antibodies with appropriate chemiluminescent substrates provide sensitive detection.

• Expected bands: Be aware that different CASP10 isoforms will produce bands of varying molecular weights. The most common forms observed are:

  • Uncleaved Pro-Caspase 10D: ~59 kDa

  • Uncleaved Pro-Caspase 10A: ~55 kDa

  • Cleaved forms: ~47 kDa and ~43 kDa

• Positive controls: Include staurosporine-treated Jurkat cells or apoptotic HeLa cells as positive controls .

How should immunohistochemistry protocols be optimized for CASP10 detection in tissue samples?

For effective CASP10 immunohistochemistry:

• Tissue fixation: Use 10% neutral buffered formalin fixation for consistent results.

• Antigen retrieval: Perform heat-induced epitope retrieval using TE buffer at pH 9.0, though citrate buffer at pH 6.0 may also be effective .

• Blocking: Use 3-5% normal serum matching the secondary antibody host species to reduce background.

• Primary antibody: Dilute antibodies appropriately (1:20-1:200 for Proteintech antibody 14311-1-AP) .

• Incubation times: Overnight incubation at 4°C often yields optimal staining.

• Detection system: Use polymer-based detection systems for improved sensitivity and reduced background.

• Positive tissue controls: Human endometrial cancer tissue has been validated as a positive control for some CASP10 antibodies .

How can researchers distinguish between CASP10 isoforms in experimental samples?

Distinguishing between CASP10 isoforms requires:

• Antibody selection: Choose antibodies that target regions specific to certain isoforms or use multiple antibodies targeting different regions.

• Western blot analysis: Different isoforms can be identified by their molecular weights:

  • Pro-Caspase 10D: ~59 kDa

  • Pro-Caspase 10A: ~55 kDa

• Cell type consideration: Different cell types may express different isoform patterns. In B-LCL and SEE T blasts, the uncleaved isoforms (Pro-Caspase 10D and 10A) are predominantly expressed, while T-LCL mainly display cleaved counterparts (47 and 43 kDa) .

• qRT-PCR approach: Use isoform-specific primers to quantify mRNA expression levels of different isoforms.

• Mass spectrometry: For definitive identification, consider targeted proteomics to distinguish between closely related isoforms.

What methodologies are recommended for studying FAS-mediated apoptosis in relation to CASP10 variants?

To study FAS-mediated apoptosis in relation to CASP10 variants:

• Cell model preparation: Generate T blasts from PBMCs or use established cell lines (B-LCL, T-LCL) .

• Apoptosis induction: Use anti-FAS antibodies or soluble FAS ligand at standardized concentrations.

• Apoptosis measurement: Employ flow cytometry with Annexin V/PI staining or TUNEL assays.

• Controls: Include both positive controls (ALPS-FAS patients with known mutations in FAS extracellular domain [ECD] or intracellular domain [ICD]) and healthy controls .

• FAS expression analysis: Measure CD95 (FAS) expression on cell surface using flow cytometry to determine if CASP10 variants affect FAS expression .

• Data analysis: Compare apoptosis percentages across different variants (heterozygous vs. homozygous) and controls, as demonstrated in studies examining p.C401LfsX15, p.V410I and p.Y446C variants .

How can researchers address potential discrepancies between CASP10 protein expression and functional assays?

To address discrepancies between expression and function:

• Protein expression analysis: Use Western blotting with antibodies targeting different domains of CASP10.

• RNA analysis: Perform qRT-PCR to determine if expression discrepancies are at the transcriptional level. RNA instability may explain some discrepancies, as seen with the p.C401LfsX15 variant .

• Functional redundancy assessment: Investigate possible compensatory mechanisms through other caspases, particularly CASP8.

• Mutation context evaluation: Consider that some mutations (like p.C401LfsX15) can abolish protein expression without impacting FAS-mediated apoptosis function, suggesting CASP10 may be dispensable for this pathway in some contexts .

• Post-translational modification analysis: Phosphorylation or other modifications may affect function without altering expression levels.

• Structural analysis: When possible, use structural biology approaches to understand how specific mutations affect protein conformation and function.

What are the potential pitfalls in interpreting CASP10 variant pathogenicity in clinical samples?

Key considerations when interpreting CASP10 variant pathogenicity:

• Population frequency assessment: Some variants previously reported as pathogenic (e.g., p.I406L) have been found at 2% frequency in healthy individuals, questioning their pathogenicity .

• Segregation analysis: Evaluate if the variant segregates with disease in families, as inconsistent familial segregation has been observed with CASP10 variants .

• Functional impact evaluation: Distinguish between variants that affect protein expression versus function. The p.C401LfsX15 variant abolishes CASP10 expression but doesn't impair FAS-mediated apoptosis .

• Clinical correlation: Not all carriers of CASP10 variants display ALPS symptoms, and some may be completely healthy .

• Polygenic considerations: Some CASP10 variants may act as disease modifiers in digenic inheritance models with other genes (like FAS) .

• Experimental validation: Conduct comprehensive protein expression and functional assays before concluding pathogenicity.

How should researchers design experiments to investigate CASP10 mutations in non-Hodgkin lymphomas?

For investigating CASP10 mutations in non-Hodgkin lymphomas:

• Sample collection: Obtain matched tumor and normal tissue samples from NHL patients.

• Mutation screening: Analyze the entire coding region and splice sites of the CASP10 gene, focusing on:

  • Prodomain

  • p17 large protease subunit

  • p12 small protease subunit

• Functional validation: Express tumor-derived CASP10 mutants in model cell lines (e.g., 293 cells) and assess their impact on apoptosis induction .

• Protein expression analysis: Use Western blotting to determine if mutations affect CASP10 protein levels.

• Apoptosis pathway analysis: Evaluate both intrinsic and extrinsic apoptotic pathways, as CASP10 may have different roles in each.

• Correlation with clinical data: Analyze associations between CASP10 mutations and clinical parameters such as lymphoma subtype, treatment response, and patient outcomes.

What methodological approaches are recommended for differentiating between CASP10-related ALPS and other forms of the disease?

To differentiate CASP10-related ALPS from other forms:

• Genetic testing: Screen for mutations in known ALPS-associated genes (FAS, FASLG, FADD) alongside CASP10 .

• Clinical criteria assessment: Evaluate patients for:

  • Lymphadenopathy

  • Splenomegaly

  • Autoimmune cytopenias

  • Elevated TCRαβ+CD4-CD8- T cells (DNTs)

• Biomarker analysis: Measure:

  • Vitamin B12 levels (normal: <1500 ng/L)

  • Soluble FAS ligand (normal: <0.2 ng/mL)

  • IL-10 levels (normal: <20 pg/mL)

• Functional assays: Compare FAS-mediated apoptosis in patient cells with:

  • Healthy controls

  • ALPS-FAS patients with ECD mutations (mild apoptosis defect)

  • ALPS-FAS patients with ICD mutations (profound apoptosis defect)

• Expression analysis: Assess CASP10 protein expression by Western blot and RNA expression by qRT-PCR.

• FAS expression evaluation: Measure CD95 expression on cell surface to rule out compensatory mechanisms .

What techniques can be employed to study the interaction between CASP10 and other components of the DISC complex?

To study CASP10 interactions with DISC components:

• Co-immunoprecipitation: Use anti-CASP10 antibodies to pull down associated proteins, followed by Western blotting for DISC components (FADD, CASP8, FLIP).

• Proximity ligation assay: Visualize protein-protein interactions in situ between CASP10 and other DISC components.

• FRET/BRET analysis: Employ fluorescence or bioluminescence resonance energy transfer to study real-time interactions in living cells.

• Mass spectrometry: Use immunoprecipitation coupled with MS to identify novel interaction partners.

• Yeast two-hybrid screening: Identify potential interaction partners through library screening.

• Structural biology approaches: Use X-ray crystallography or cryo-EM to determine the structural basis of interactions.

• CRISPR-Cas9 editing: Generate cells with tagged endogenous CASP10 for more physiological interaction studies.

How can researchers investigate the potential compensatory mechanisms when CASP10 function is compromised?

To investigate compensatory mechanisms when CASP10 is compromised:

• Expression profiling: Perform RNA-seq on cells with CASP10 deficiency or mutations to identify upregulated genes.

• Protein analysis: Use proteomic approaches to identify changes in protein expression or post-translational modifications.

• Double knockout studies: Generate CASP10 and potential compensatory gene (e.g., CASP8) double knockout cells to test for synthetic lethality.

• Pathway inhibition: Use small molecule inhibitors to block potential compensatory pathways and observe effects on cell viability.

• Time-course experiments: Analyze expression changes over time following CASP10 inhibition to identify early vs. late compensatory mechanisms.

• Cell type specificity: Compare compensatory mechanisms across different cell types, as studies have shown that CASP10-deficient individuals may have normal FAS-mediated apoptosis without upregulation of FAS expression .

• CASP10 isoform analysis: Investigate whether different isoforms may have opposite impacts on apoptosis regulation, as suggested by pre-clinical data .